Pre-made Avizakimab benchmark antibody ( Whole mAb, anti-IL21 therapeutic antibody, Anti-CVID11/IL-21/Za11 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Avizakimab biosimilar, Whole mAb, Anti-IL21 Antibody: Anti-CVID11/IL-21/Za11 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Avizakimab (formerly BOS 161721) is a fully human anti-interleukin 21 monoclonal antibody, being developed by Boston Pharmaceuticals, for treatment of autoimmune disorders including systemic lupus erythematosus.
| Products Name (INN Index) | Pre-Made Avizakimab biosimilar, Whole mAb, Anti-IL21 Antibody: Anti-CVID11/IL-21/Za11 therapeutic antibody |
|---|---|
| INN Name | Avizakimab |
| Target | IL21 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | MedImmune,Boston Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Systemic lupus erythematosus |
| Conditions Discontinued | Autoimmune disorders |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL21 |
| Package |
